🇺🇸 FDA
Pipeline program

601

SSGJ-601-pmCNV-II-01

Phase 2 small_molecule active

Quick answer

601 for Pathological Myopic Choroidal Neovascularization is a Phase 2 program (small_molecule) at Sunshine Biopharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Sunshine Biopharma
Indication
Pathological Myopic Choroidal Neovascularization
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials